J&J presses pause on a partner's PhI prostate cancer study, cutting off potential Erleada combo
J&J has decided to hit the brakes on one of its partner’s early-stage programs.
The Big Pharma’s Janssen division will halt enrollment in ESSA Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
